This is a routine CFO appointment with no immediate market-moving implications. Monitor for updates on FDA approval of the SSi Mantra system and any capital markets activity, as the new CFO's capital-raising experience may signal future financing.
Price Chart
Executive Summary
SS Innovations appointed Sarah M. Romano as CFO effective August 3, 2026, with a three-year employment agreement providing $440,000 base salary, 40% target annual bonus, and 750,000 stock options vesting over three years. Ms. Romano brings over two decades of medtech finance experience, including CFO roles at Vicarious Surgical, Entero Therapeutics, and Kiora Pharmaceuticals, and has raised over $100 million in capital. The appointment fills the CFO role with a U.S.-based executive as the company pursues FDA approval for its SSi Mantra surgical robotic system.
Key Facts
- Sarah M. Romano appointed CFO, effective August 3, 2026
- Three-year employment agreement with $440,000 annual base salary
- Target annual bonus of 40% of base salary based on performance criteria
- Grant of options to purchase 750,000 shares under the 2026 Incentive Stock Plan, vesting over three years
- Prior CFO roles at Vicarious Surgical (RBOT), Entero Therapeutics (ENTO), and Kiora Pharmaceuticals (KPRX)
- Company pursuing U.S. FDA approval for its SSi Mantra surgical robotic system
Financial Impact
No material financial impact; executive compensation disclosed is standard for a CFO hire
Risk Factors
- No specific risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-077784 |
| Document: ea0297601-8k_ssinnova.htm | 0001213900-26-077784 |
| Document: ea029760101ex99-1.htm | 0001213900-26-077784 |
| Document: 0001213900-26-077784-index-headers.html | 0001213900-26-077784 |
| Document: 0001213900-26-077784-index.html | 0001213900-26-077784 |
| Document: 0001213900-26-077784.txt | 0001213900-26-077784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $2.37 | awaiting T+5 | — | $2.50 (+5.49%) |
Oct 26, 2026 1d ago | Press Release | $2.37 | awaiting T+5 | — | $2.50 (+5.49%) |
Oct 13, 2026 14d ago | 8-K | $2.55 $2.54 | ▼ −0.39% | ▲ +0.76% | $2.50 (−1.96%) |
Oct 13, 2026 14d ago | 8-K | $2.55 $2.54 | ▲ +0.39% | ▼ −0.76% | $2.50 (+1.96%) |
Oct 9, 2026 18d ago | 424B5 | $2.55 $2.45 | ▲ +3.92% | ▲ +2.43% | $2.50 (+1.96%) |
Oct 5, 2026 22d ago | 8-K | $2.77 $2.55 | ▼ −7.94% | ▼ −8.36% | $2.50 (−9.75%) |
Sep 10, 2026 6w ago | 8-K | $3.30 $3.26 | ▼ −1.21% | ▼ −0.71% | $2.50 (−24.24%) |
Aug 13, 2026 10w ago | 8-K | $3.83 $3.61 | ▼ −5.74% | ▼ −3.78% | $2.50 (−34.73%) |
Jul 17, 2026 14w ago | 8-K | $3.64 $3.57 | ▼ −1.92% | ▼ −1.24% | $2.50 (−31.32%) |
Jul 14, 2026 15w ago | 8-K | $3.67 $3.75 | ▲ +2.18% | ▲ +3.48% | $2.50 (−31.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers